Biora Therapeutics (NASDAQ:BIOR – Get Free Report) and CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.
Valuation & Earnings
This table compares Biora Therapeutics and CASI Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biora Therapeutics | $892,000.00 | 0.71 | -$124.11 million | ($13.04) | -0.01 |
| CASI Pharmaceuticals | $33.88 million | 1.17 | -$26.94 million | ($2.23) | -1.14 |
CASI Pharmaceuticals has higher revenue and earnings than Biora Therapeutics. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Biora Therapeutics | N/A | N/A | -332.47% |
| CASI Pharmaceuticals | -143.18% | -181.52% | -45.72% |
Institutional & Insider Ownership
43.7% of Biora Therapeutics shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 51.1% of Biora Therapeutics shares are held by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings for Biora Therapeutics and CASI Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biora Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| CASI Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Biora Therapeutics currently has a consensus price target of $23.00, suggesting a potential upside of 16,212.06%. CASI Pharmaceuticals has a consensus price target of $6.00, suggesting a potential upside of 135.29%. Given Biora Therapeutics’ higher possible upside, research analysts clearly believe Biora Therapeutics is more favorable than CASI Pharmaceuticals.
Risk & Volatility
Biora Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Summary
Biora Therapeutics beats CASI Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About Biora Therapeutics
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Receive News & Ratings for Biora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
